At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 608 enrolled
Drug / intervention
Desloratadine 5 mg +1 moredrug
Likely dose
Desloratadine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Desloratadine 5 mg and Placebo for Perennial Allergic Rhinitis. Completed, enrolled 608 participants.
Detailed Summary
This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine is superior to placebo after 2 weeks of treatment with regard to change from baseline in Total Nasal Symptom Score among Japanese participants with perennial allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartAug 2013
Primary CompletionJan 2014
TodayJul 2026
First PostedAug 7, 2013
Enrollment StartAug 20, 2013
Primary CompletionJan 26, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.9 years ago
Interventions
Desloratadine 5 mgdrug
Desloratadine 5 mg tablets
Placebodrug
Matching placebo to desloratadine 5 mg tablets